Researchers are studying a new medicine called patritumab deruxtecan (MK-1022) to see if it can help treat certain gastrointestinal (GI) cancers. GI cancer occurs in parts of your body where food passes through, like the stomach and intestines. This study focuses on advanced cancers, meaning cancers that have spread to other body parts. The study aims to learn if this medicine is safe and how well people can handle it, as well as how many people's cancer gets smaller or goes away with the treatment. If you want to be part of this study, you must have a type of cancer such as unresectable (not removable by surgery) or metastatic colorectal cancer, advanced biliary tract cancer (BTC), or hepatocellular carcinoma (HCC). You should have had cancer treatment before and recovered from any side effects. You aren't eligible if you have severe lung issues, serious eye disease, or uncontrolled heart or brain problems.

• The study involves advanced GI cancer patients.
• Participants must have prior cancer therapy.
• Exclusion if severe lung, eye, heart, or brain issues exist.